IC
MGRX icon

Ikarian Capital’s Mangoceuticals MGRX Stock Holding History

Ikarian Capital’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.7K Hold
138,146
– – ﹤0.01% 154
2025
Q4 		$102K Buy
+138,146
New +$224K 0.01% 163

Other funds holding MGRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $488M AUM 14.36% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Ikarian Capital's MGRX Position: Q1 2026 in Review

Ikarian Capital held its Mangoceuticals (MGRX) position steady in Q1 2026 at 138,146 shares worth $49.7K. The position accounts for ﹤0.01% of the portfolio, ranked #154.

Ikarian Capital first reported a position in MGRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $102K in Q4 2025. 18 funds tracked by Wall St. Rank hold MGRX as of Q1 2026.

  • Ikarian Capital held 138,146 shares of Mangoceuticals worth $49.7K as of Q1 2026.
  • Ikarian Capital left its Mangoceuticals share count unchanged in Q1 2026.
  • Mangoceuticals made up ﹤0.01% of Ikarian Capital's portfolio in Q1 2026, its #154 holding.
  • Ikarian Capital first reported a position in Mangoceuticals in Q4 2025 and has held it in 2 quarters since.
  • Ikarian Capital's Mangoceuticals position peaked at $102K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.